John A. Zuris, et al. Highly Efficient Single and Multi-gene Knockout with CRISPR-Cpf1 in T Cells for the Development of Improved Cell Therapies. Presented at the European Society of Gene & Cell Therapy (ESGCT) 26th Annual Congress, October 16 – 19.

Dec

12

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec

9

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Nov

6

Editas Medicine to Participate in Upcoming Investor Conferences